Bioartificial liver with whole blood perfusion.
In our series of studies, we have made an effort to develop a bioartificial liver (BAL) system through which whole blood can be perfused as in hemodialysis therapy. In this study, BAL cartridges containing porcine hepatocytes were prepared and perfused in an extracapillary space with human whole blood in vitro. Lidocaine loading tests were performed to evaluate the detoxification ability of the BAL. The clearance value of lidocaine decreased during the initial 6 hours to about 50% of the initial value. After that, it was almost stable until 48 hours. After 48 hours perfusion, thin sections of the hollow fibers containing hepatocytes were prepared and stained with hematoxylin-eosin and immunohistochemically stained for membrane attack complex (MAC). The porcine hepatocytes formed aggregates in the hollow fibers, nuclei in the cells were observed clearly, and MAC was not seen on the porcine hepatocyte aggregation. A hollow fiber that can reject 90% of molecules with molecular weight of 50 kDa effectively protects porcine hepatocytes from humoral immunity. The in vivo assessment of the BAL cartridge was performed using a canine model for 24 hours. No significant hemolysis or thrombus that affected the BAL system and the canine were observed. These results suggest that our BAL system is a promising liver assist device through which patients' whole blood can be perfused.
Ueda
Yuichiro
Y
Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
Iwata
Hiroo
H
Paek
Hyun Joon
HJ
Ko
In Kap
IK
Shimooka
Yutaka
Y
Katsura
Nagato
N
Ikai
Iwao
I
Yamaoka
Yoshio
Y
Ikada
Yoshito
Y
D000818:Animals; D000917:Antibody Formation; D001769:Blood; D004285:Dogs; D004867:Equipment Design; D022781:Hepatocytes / Q000276:immunology / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008658:Inactivation, Metabolic; D008012:Lidocaine / Q000378:metabolism; D019164:Liver, Artificial; D010477:Perfusion; D034421:Sus scrofa
D008012:Lidocaine